Vanguard Capital Management’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Vanguard Capital Management's RNA Position: Q3 2026 in Review
Vanguard Capital Management reduced its Atrium Therapeutics (RNA) stake by 0.11% in Q3 2026, selling an estimated $9.5K and leaving 730,026 shares worth $6.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3008.
Vanguard Capital Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $9.8M in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Vanguard Capital Management held 730,026 shares of Atrium Therapeutics worth $6.04M as of Q3 2026.
- Vanguard Capital Management sold 805 Atrium Therapeutics shares in Q3 2026, an estimated $9.5K.
- Atrium Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3008 holding.
- Vanguard Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Atrium Therapeutics position peaked at $9.8M in Q2 2026.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.